1
|
Deloumeaux J, Bhakkan-Mambir B, Desroziers L, Plenet J, Peruvien J, Chatignoux É, Belliardo S, Macni J, Ulric-Gervaise S, Véronique-Baudin J, Joachim C. Urological Cancers in French Overseas Territories: A Population-Based Cancer Registry Pooled Analysis in Martinique, Guadeloupe and French Guiana (2007-2014). J Epidemiol Glob Health 2022; 12:232-238. [PMID: 35041179 PMCID: PMC9470795 DOI: 10.1007/s44197-022-00033-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Accepted: 01/06/2022] [Indexed: 12/24/2022] Open
Abstract
Purpose Prostate cancer is the most common cancer in the Caribbean. We present world-standardized incidence (WSI) and mortality (WSM) rates for urological cancers for French overseas territories. Materials and Methods Standardized incidence ratio (SIR) and standardized mortality ratio (SMR) were calculated for 2008–2014, 2007–2014 and 2010–2014 in Guadeloupe, Martinique and French Guiana. Results For prostate cancer, in Guadeloupe and Martinique, the WSI rates are among the highest in the world (173.0 and 164.5 per 100,000 person-years) and 94.4 in French Guiana. Mortality remains more than twice that observed in mainland France, at 23.0 in Guadeloupe and Martinique, and 16.9 in French Guiana. For bladder cancer, WSI rates were 5.9, 4.9 and 4.1 in men, and 1.9, 1.4 and 1.3 in women, in French Guiana, Guadeloupe and Martinique. WSM rates from bladder varied from 1.5 in French Guiana to 1.8 in Guadeloupe and 2.0 in Martinique in men. In women, it ranges from 0.2 in French Guiana to 0.5 in Guadeloupe and 1.1 in Martinique. Regarding kidney, WSI rates in men are 4.3 in Martinique, 5.2 in Guadeloupe and 6.1 in French Guiana, and 2.3, 2.5 and 3.4, respectively, in women. Mortality rates in men were 1.7 in Guadeloupe, 1.4 in Martinique, and 1.5 in French Guiana, while in women, rates were 0.8 in Guadeloupe and Martinique and 0.6 in French Guiana. All these rates are lower than in mainland France. Conclusions Identifying the profile of patients with urological cancers is key to understanding the needs of patients in these regions.
Collapse
Affiliation(s)
- Jacqueline Deloumeaux
- Registre Général des Cancers de Guadeloupe, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe F.W. I., Route de Chauvel, 97159 Pointe-à-Pitre Cedex, France
| | - Bernard Bhakkan-Mambir
- Registre Général des Cancers de Guadeloupe, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe F.W. I., Route de Chauvel, 97159 Pointe-à-Pitre Cedex, France
| | | | | | - Jessica Peruvien
- Registre Général des Cancers de Guadeloupe, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe F.W. I., Route de Chauvel, 97159 Pointe-à-Pitre Cedex, France
| | - Édouard Chatignoux
- French National Public Health Agency, 12 rue du Val d’Osne, 94410 Saint Maurice, France
| | | | - Jonathan Macni
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie, UF 1441 Registre Général des Cancers de la Martinique, Fort de France, 97200 Martinique
| | - Stephen Ulric-Gervaise
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie, UF 1441 Registre Général des Cancers de la Martinique, Fort de France, 97200 Martinique
| | - Jacqueline Véronique-Baudin
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie, UF 1441 Registre Général des Cancers de la Martinique, Fort de France, 97200 Martinique
| | - Clarisse Joachim
- CHU de Martinique, Pôle de Cancérologie Hématologie Urologie, UF 1441 Registre Général des Cancers de la Martinique, Fort de France, 97200 Martinique
- Hôpital Albert Clarac, Avenue Pasteur, CS 90632, 97200 Fort de France, Martinique
| |
Collapse
|
2
|
Ondo CZ, Ndiath A, Sarr A, Thiam A, Sine B, Sow O, Ndour NS, Diao B, Fall PA, Ndoye AK. Metastatic prostate cancer: clinical aspects and treatment limitations in a university hospital center in Senegal. AFRICAN JOURNAL OF UROLOGY 2021. [DOI: 10.1186/s12301-021-00223-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
Prostate cancer is most often diagnosed at the metastatic stage in many sub-Saharan African countries. The objective of our study is to analyze the management of metastatic prostatic adenocarcinoma based on epidemiological, clinical, therapeutic and evolutionary aspects in developing country context.
Methods
Retrospective study collecting 276 patients from January 1st, 2012 to December 31st, 2019 in Aristide Le Dantec University Hospital in Dakar, Senegal. Parameters studied: age, family history of prostate cancer, reasons for consultation, total Prostate Specific Antigen (PSA), anatomic pathology examination, extension assessment, treatment, nadir PSA, castration resistance, and overall survival.
Results
The average age was 71.4 years. A family history of prostate cancer was noted in 21 patients. Spinal pain was the most noted reason for consultation. The average total PSA level was 1967.1 ng/ml. The majority of patients had moderately differentiated prostate cancer. Bone metastases were the most common. All patients had androgen suppression. A tumor cytoreduction was performed in 89 patients. The average nadir PSA was 193 ng/ml as early as the sixth month. The time to onset of castration resistance ranged from 6 to 30 months. Abiraterone acetate was used in seven patients and docetaxel in 43 patients. The overall survival of the patients was 19.8 ± 1.2 months.
Conclusion
Metastatic prostate cancer was most often symptomatic at the time of diagnosis. Second-line treatments were rarely used during castration resistance. Overall survival was low.
Collapse
|
3
|
Joachim C, Veronique-Baudin J, Ulric-Gervaise S, Macni J, Almont T, Pierre-Louis O, Godaert L, Drame M, Novella JL, Farid K, Vinh-Hung V, Escarmant P. Pattern of care of prostate cancer patients across the Martinique: results of a population-based study in the Caribbean. BMC Cancer 2018; 18:1130. [PMID: 30445934 PMCID: PMC6240273 DOI: 10.1186/s12885-018-5047-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Accepted: 11/06/2018] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND The French West-Indies rank first for both prostate cancer incidence and mortality rates. Analyzing diagnostic and therapeutic procedures among patients with prostate cancer, using data from a population-based cancer registry, is essential for cancer surveillance and research strategies. METHODS This retrospective observational cohort study was based on data from the Martinique Cancer Registry. Records of 452 patients diagnosed with prostate cancer in 2013 were retrieved from the registry. Data extracted were: socio-demographic and clinical characteristics, circumstances of diagnosis, PSA level at diagnosis, Gleason score and risk of disease progression. Stage at diagnosis and patterns of care among prostate cancer patients were analyzed. RESULTS Mean age at diagnosis was 67 ± 8 years; 103 (28.5%) were symptomatic at diagnosis. Digital rectal exam was performed in 406 (93.8%). Clinical stage was available in 385 (85.2%); tumours were localized in 322/385 (83.6%). Overall, 17.9% were at low risk, 36.4% at intermediate and 31.9% at high risk; 13.8% were regional/metastatic cancers. Median PSA level at diagnosis was 8.16 ng/mL (range 1.4-5000 ng/mL). A total of 373 patients (82.5%) received at least one treatment, while 79 (17.5%) had active surveillance or watchful waiting. Among patients treated with more than one therapeutic strategy, the most frequent combination was external radiotherapy with androgen deprivation (n = 102, 22.6%). CONCLUSIONS This study provides detailed data regarding the quality of diagnosis and management of patients with prostate cancer in Martinique. Providing data on prostate cancer is essential for the development of high-priority public health measures for the Caribbean.
Collapse
Affiliation(s)
- Clarisse Joachim
- CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CS 90632, 97200, Fort-de-France, Martinique, France.
| | - Jacqueline Veronique-Baudin
- CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CS 90632, 97200, Fort-de-France, Martinique, France
| | - Stephen Ulric-Gervaise
- CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CS 90632, 97200, Fort-de-France, Martinique, France
| | - Jonathan Macni
- CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CS 90632, 97200, Fort-de-France, Martinique, France
| | - Thierry Almont
- CHU Toulouse Paule de Viguier, Groupe de recherche en fertilité humaine EA 3694, Toulouse, France.,Groupe d'Étude, de Formation et de Recherche en Andrologie, Urologie et Sexologie Médecine de la Reproduction, Toulouse, France
| | - Olivier Pierre-Louis
- CHU Martinique, Pôle de Cancérologie, Hématologie Urologie Pathologie, 97200 Fort-de-France, Martinique, France
| | - Lidvine Godaert
- CHU de Martinique, Pôle de Gériatrie, 97200 Fort-de-France, Martinique, France
| | - Moustapha Drame
- CHU de Reims, Pôle Recherche et Santé publique, 51100 Reims, France
| | | | - Karim Farid
- CHU Martinique, Pole d'imagerie Médicale Service de Médecine nucléaire, 97200 Fort-de-France, Martinique, France
| | - Vincent Vinh-Hung
- CHU MARTINIQUE, Pôle de Cancérologie Hématologie Urologie Pathologie, 97200 Fort-de-France, Martinique, France
| | - Patrick Escarmant
- CHU MARTINIQUE, Pôle de Cancérologie Hématologie Urologie Pathologie, 97200 Fort-de-France, Martinique, France
| |
Collapse
|